Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9950 Phase 1 in Healthy and Chronic Hepatitis B Subjects
NCT04464733Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS9950 in Chronic Hepatitis B (CHB) (15 arms), sponsored by Hengrui. Primary endpoints: Incidence and severity of treatment-related adverse events at 50 days, Maximum Plasma Concentration at Day 22 and 7 more. Started Jul 2020; status: completed.
02
Drugs
HRS9950
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04464733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464733.